Company intelligence / Profile preview
Nascent Biotech
North Palm Beach, Florida, USAnascentbiotech.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Nascent Biotech’s lead candidate, pritumumab, is a human monoclonal antibody that has completed Phase 1 trials demonstrating safety at multiple ascending cohorts. It has advanced to Phase 2 clinical trials for brain cancer. The company also explores combination therapies using cocktails of antibodies and cytokines to mimic natural immune responses
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Monoclonal antibodyAntibody-drug conjugate
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Manhattan BioSolutionsBioRay Pharmaceutical Co.
Beyond the preview
Go deeper on Nascent Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nascent Biotech.